- Supported exchanges /
- F /
- 3XI.F
BIOMIND LABS INC. (3XI F) stock market data APIs
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; and BMND08, a 5-Methoxy-N,N-dimethyltryptamine based candidate that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer's-type cognitive impairment. It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammatory disorders, and BMND07 for treating major depressive disorder. The company is headquartered in Canelones, Uruguay.
BIOMIND LABS INC. Financial Data Overview
0.218 | |
0.218 | |
- | |
0.218 | |
0.218 | |
0.0005-0.482 | |
17 537 K | |
74 762 K | |
0 | |
-0.003 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
BIOMIND LABS INC. Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -1 444 642
- Earnings Per Share -0.01
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get BIOMIND LABS INC. Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get BIOMIND LABS INC. End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: